An industry-focused, end-to-end meeting covering neurodegenerative R&D from early discovery through late-stage clinical and ...

The release of Phase III Stage 1 data for gotistobart (BNT316/ONC-392) at NACLC 2025 marks one of the most significant ...

Gilead Sciences subsidiary Kite and its partner Arcellx have announced new positive data from the pivotal iMMagine-1 Phase II ...

Belgian biotech Galapagos reported new Phase II results for its fresh, memory-enriched CAR T candidate GLPG5101 in relapsed ...

Dutch biotech Pan Cancer T has raised 10 million euros ($11 million) to advance its lead cell therapy, PCT1:CO-STIM, into a ...

German biotech BioNTech USA-based OncoC4 yesterday presented data from the non-pivotal dose-confirmation stage of the global ...

Denmark-based clinical-stage techbio Evaxion Biotech, which is specializing in developing AI-Immunology powered vaccines, ...

A German court has ordered Merck & Co (NYSE: MRK) to halt launch preparations for its new subcutaneous version of Keytruda ...

Belgium’s UCB has presented positive efficacy and safety results from the GEMZ Phase III study investigating adjunctive ...

The USA’s immunization advisers have voted to shift long-standing guidance on hepatitis B vaccination for newborns, ...

US rare disease drug developer Mirum Pharmaceuticals today announced its entry into a definitive agreement to acquire Bluejay ...

Swiss incubator Xlife Sciences today announced that Mexico-based Grupo Landsteiner has signed a binding framework to acquire ...